Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year
By Sabela Ojea
Invivyd said it expects net product revenue of $150 million to $200 million this year from its Covid-19 preventive treatment, shortly after receiving an emergency use authorization from the Food and Drug Administration.
The biotechnology company on Thursday said that based on expected net product revenue on the treatment for the year, it also expects to end 2024 with at least $55 million in cash and cash equivalents.
The pre-Covid-19 exposure injection Pemgarda is now commercially available for purchase across the U.S.
On March 22, Invivyd said the FDA granted the emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 04, 2024 16:38 ET (20:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing